Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Vertex Pharmaceuticals Inc. closed 9.68% short of its 52-week high of $519.88, which the company reached on November 8th.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...